Interestingly, a notable change in T2D patients was the upregulated surface expression of SLAMF3 on T cells, including both CD4+ and CD4− T-cell subsets (Fig. 1), suggesting a possible involvement of SLAMF3 signaling in altered immune responses in T2D patients. The gene discussed is LY9; the disease is type 2 diabetes mellitus.